650 results match your criteria VIPomas

Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study.

Adv Ther 2021 May 4. Epub 2021 May 4.

Device Development, Sun Pharmaceutical Industries Ltd, Tandalja, Vadodara, Gujarat, India.

Introduction: Octreotide acetate subcutaneous injection is indicated to treat acromegaly and the symptoms of carcinoid tumors and vasoactive intestinal peptide tumors (VIPomas). This formative human factors study assessed the octreotide acetate pen injector and accompanying instructions for use (IFU) with self-trained participants.

Methods: The study enrolled patients with diagnoses of acromegaly, carcinoid tumors, or VIPomas and healthcare practitioners (HCPs) who treat patients with these diagnoses. Read More

View Article and Full-Text PDF

Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d'étude des Tumeurs Endocrines) Study.

World J Surg 2021 Jun 1;45(6):1794-1802. Epub 2021 Mar 1.

Department of Digestive and Endocrine Surgery, Dijon University Hospital, University of Burgundy, Dijon, France.

Aim: To assess postoperative complications and control of hormone secretions following pancreatoduodenectomy (PD) performed on multiple endocrine neoplasia type 1 (MEN1) patients with duodenopancreatic neuroendocrine tumors (DP-NETs).

Background: The use of PD to treat MEN1 remains controversial, and evaluating the right place of PD in MEN1 disease makes sense.

Methods: Thirty-one MEN1 patients from the Groupe d'étude des Tumeurs Endocrines MEN1 cohort who underwent PD for DP-NETs between 1971 and 2013 were included. Read More

View Article and Full-Text PDF

Repurposing calcium-sensing receptor agonist cinacalcet for treatment of CFTR-mediated secretory diarrheas.

JCI Insight 2021 Feb 22;6(4). Epub 2021 Feb 22.

Department of Pediatrics and.

Diarrhea is a major cause of global mortality, and outbreaks of secretory diarrhea such as cholera remain an important problem in the developing world. Current treatment of secretory diarrhea primarily involves supportive measures, such as fluid replacement. The calcium-sensing receptor (CaSR) regulates multiple biological activities in response to changes in extracellular Ca2+. Read More

View Article and Full-Text PDF
February 2021


Georgian Med News 2020 Nov(308):101-109

Bogomolets National Medical University, Kyiv, Ukraine TARGET Oncology Clinic, Kyiv, Ukraine.

Pancreatic neuroendocrine tumors (NETs) are an urgent problem. The issues of diagnosis and treatment of neuroendocrine tumors (NETs) are currently one of the most complex and relevant ones in modern oncological endocrinology. The growing interest in NETs is due to the fact that the incidence rate of this pathology has increased significantly in the world over the past 30-35 years. Read More

View Article and Full-Text PDF
November 2020

Pancreatic neuroendocrine tumors: Surgical outcomes and survival analysis.

Am J Surg 2021 03 24;221(3):529-533. Epub 2020 Dec 24.

Loyola University Medical Center, Department of Surgery, Maywood, IL, USA.

Background: Pancreatic neuroendocrine tumors are rare, with rising incidence and limited clinicopathological studies.

Methods: Adult patients with pNET at a single tertiary care center were retrospectively evaluated.

Results: In total, 87 patients with histologically confirmed pNET who underwent resection were evaluated. Read More

View Article and Full-Text PDF

Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.

Histol Histopathol 2020 Dec 11:18288. Epub 2020 Dec 11.

School of Medicine, Griffith University, Gold Coast, QLD, Australia.

The nomenclature and classification of pancreatic neuroendocrine neoplasms has evolved in the last 15 years based on the advances in knowledge of the genomics, clinical behaviour and response to therapies. The current 2019 World Health Organization classification of pancreatic neuroendocrine neoplasms categorises them into three groups; pancreatic neuroendocrine tumours (PanNETs)(grade 1 grade 2, grade 3), pancreatic neuroendocrine carcinomas and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) based on the mitotic rate, Ki-67 index, morphological differentiation and/or co-existing tissue subtype. PanNETs are also classified into non-functional NET, insulinoma, gastrinoma, VIPoma, glucagonoma, somatostatinoma, ACTH-producing NET and serotonin producing NET based on hormone production and clinical manifestations. Read More

View Article and Full-Text PDF
December 2020

Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.

Int J Endocrinol 2020 6;2020:1030518. Epub 2020 Nov 6.

Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China.

Background: Functional pancreatic neuroendocrine neoplasms (PanNENs) are very rare disorders but have complex spectrum, including insulinoma, gastrinoma, glucagonoma, somatostatinoma, and VIPoma. Patients with PanNENs usually present with characteristic symptoms caused by corresponding hormone hypersecretion. It has always been challenging in dealing with such rare but complicated disorders. Read More

View Article and Full-Text PDF
November 2020

Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes.

Expert Opin Pharmacother 2021 Apr 11;22(6):685-693. Epub 2020 Nov 11.

Digestive Diseases Branch, NIDDK,NIH, Bethesda, MD, USA.

: In the past, controlling the hormone-excess-state was the main determinant of survival in Functional-Neuroendocrine-Neoplasm-syndromes (F-NENs). This was difficult because the pharmacological-armamentarium available was limited. Recently, new therapeutic strategies have increased but it also generated controversies/uncertainties. Read More

View Article and Full-Text PDF

Vasoactive intestinal peptide-oma causing refractory diarrhea in a young woman.

Proc (Bayl Univ Med Cent) 2020 Jul 7;33(4):641-643. Epub 2020 Jul 7.

Division of Gastroenterology, Baylor University Medical Center, Dallas, Texas.

Vasoactive intestinal peptide (VIP)-secreting neuroendocrine tumors are an exceptionally rare cause of chronic diarrhea. We describe a 36-year-old woman presenting with a 2-year history of severe diarrhea and electrolyte derangements ultimately diagnosed with VIPoma. Read More

View Article and Full-Text PDF

An Unusual Cause of Watery Diarrhea.

Gastroenterology 2021 Feb 8;160(3):671-674. Epub 2020 Oct 8.

Department of Medicine, Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, Illinois.

View Article and Full-Text PDF
February 2021

Percutaneous Cryoablation of Recurrent Pancreatic Mass for Life-Threatening Pancreatic VIPoma Syndrome: A Case Report.

Cardiovasc Intervent Radiol 2021 Jan 10;44(1):163-166. Epub 2020 Sep 10.

Division of Interventional Radiology, Department of Medical Imaging, London Health Sciences Centre, Western University, London, ON, Canada.

We present the case of a 73-year-old female who underwent percutaneous cryoablation for recurrent life-threatening pancreatic vasoactive intestinal polypeptide-producing tumor (VIPoma) following a pancreaticoduodenectomy and chemotherapy 5 years earlier. She presented with profuse watery diarrhea causing severe electrolyte and acid-base abnormalities, along with acute kidney injury. Cryoablation was successful in treating her profound symptoms, completely reversing her clinical course. Read More

View Article and Full-Text PDF
January 2021

Rare Cases of Pediatric Vasoactive Intestinal Peptide Secreting Tumor With Literature Review: A Challenging Etiology of Chronic Diarrhea.

Front Pediatr 2020 5;8:430. Epub 2020 Aug 5.

Division of Pediatric Gastroenterology, Department of Pediatrics, Chang Gung Memorial Hospital, Linkou Branch and Chang Gung University College of Medicine, Taoyuan City, Taiwan.

Vasoactive intestinal peptide (VIP) secreting tumor (VIPoma) is a rare disease, presenting with profuse diarrhea, electrolyte imbalance, and possibly fatal outcome. The diagnosis and treatment are challenging, and no consensus guideline of management is available. The pediatric incidence remains unclear. Read More

View Article and Full-Text PDF

Incidental 68Ga-DOTATATE uptake in the pancreatic head: A case report and a unique opportunity to improve clinical care.

Medicine (Baltimore) 2020 May;99(22):e20197

Radiology and Imaging Sciences, Clinical Center.

Rationale: Neuroendocrine tumors (NETs) are neoplasms that can arise from the neuroendocrine cells distributed widely throughout the body. Majority of NETs overexpress somatostatin receptors (SSTR) on their cell surface. This biologic characteristic is exploited by SSTR-based imaging such as In octreotide scintigraphy and Ga DOTATATE positron emission tomography (PET)/computed tomography (CT), which are considered standard for initial evaluation of NETs. Read More

View Article and Full-Text PDF

A Rare Cause of Refractory Chronic Diarrhea and Cachexia: A Case Report.

Iran J Public Health 2020 Feb;49(2):386-388

Department of Endocrinology, Hedi Chaker Hospital, Sfax, Tunisia.

VIPoma is an unusual neuroendocrine neoplasm that autonomously secretes VIP. It is associated with secretory diarrhea and electrolyte disturbances. Herein we report a case of a male patient, who was hospitalized in the Department of Endocrinology in Hedi Chaker Hospital, Sfax, Tunisia. Read More

View Article and Full-Text PDF
February 2020

Neuroendocrine pancreatic tumor causing chronic diarrhea in young adult, a case report.

AME Case Rep 2020 30;4:13. Epub 2020 Apr 30.

Digestive System Surgery Service at Getúlio Vargas Teaching Hospital (HUGV), Manaus, Amazonas, Brazil.

Secretory tumors of vasoactive intestinal polypeptides (VIPomas) are rare neuroendocrine pancreatic neoplasms usually associated with secretory diarrhea. Most cases present themselves with diarrhea, weight loss, and hypokalemia. Although VIPoma patients share easily distinguishable symptoms, early diagnosis remains a challenge. Read More

View Article and Full-Text PDF

Hypercalcemia in a Patient Diagnosed with a Vasoactive Intestinal Peptide Tumor.

Cureus 2020 Feb 4;12(2):e6882. Epub 2020 Feb 4.

Medicine, Renaissance School of Medicine, Stony Brook University, Stony Brook, USA.

Hypercalcemia is a clinical problem that is commonly seen in both the inpatient and outpatient settings. Overall, most common causes of hypercalcemia include hyperparathyroidism and malignancy. Our case report is the presentation of hypercalcemia in a patient eventually diagnosed with a vasoactive intestinal peptide tumor, a type of neuroendocrine tumor, without associated hyperparathyroidism. Read More

View Article and Full-Text PDF
February 2020

[Use of a somatostatin analog to improve a patient's condition and the subsequent diagnosis of pancreatic VIPoma:a case report].

Nihon Shokakibyo Gakkai Zasshi 2020 ;117(1):84-91

Department of Pathology, Fukuyama City Hospital.

A 68-year-old woman with an 11-day history of sudden abdominal pain and severe watery diarrhea was transferred to our hospital due to an exacerbation of renal function despite hydration. After treatment for dehydration and acidemia was provided in our intensive care unit, patient's renal function improved. Contrast-enhanced abdominal computed tomography was finally performed, revealing a hypervascular pancreatic mass with multiple hepatic masses. Read More

View Article and Full-Text PDF
January 2020

Successful Treatment of Hypokalemic Rhabdomyolysis Caused by a Pancreatic VIPoma: A Case Report.

Am J Case Rep 2019 Nov 22;20:1723-1727. Epub 2019 Nov 22.

Department of Pathology, Orlando Regional Healthcare, Orlando, FL, USA.

BACKGROUND VIPomas are rare neuroendocrine tumors typically located in the pancreas. The majority of cases autonomously secret vasoactive intestinal polypeptide (VIP), which can result in profuse, refractory, watery diarrhea. The fluid and electrolyte imbalance can progress to dehydration and profound hypokalemia, resulting in the watery diarrhea, hypokalemia, achlorhydria (WDHA) syndrome. Read More

View Article and Full-Text PDF
November 2019

Prevalence of Diagnostic Methods and Treatment Modalities in Vipoma Patients: A Rare Cause of Hormone-Mediated Diarrhea.

Indian J Endocrinol Metab 2019 May-Jun;23(3):318-325

Imam Khomeini Hospital Complex, Faculty of Medicine, National Tehran University of Medical Sciences, Tehran, Iran.

Introduction: VIPoma is a neuroendocrine tumor that secrets vasoactive intestinal peptide and produces a well-defined clinical syndrome characterized by watery diarrhea, hypokalemia, hypochlorhydria and metabolic acidosis. The aim of this study to investigate clinical studies about diagnostic and therapeutic modalities of vipoma patients. In this retrospective study, all patients of vipoma were investigated. Read More

View Article and Full-Text PDF
October 2019

Vasoactive Intestinal Peptide-Secreting Tumors: A Review.

Pancreas 2019 10;48(9):1119-1125

Gastroenterology Division, Mayo Clinic, Rochester, MN.

Vasoactive intestinal peptide-secreting tumors (VIPomas) are a group of rare neuroendocrine tumors, which cause a typical syndrome of watery diarrhea. Most of these tumors are found in the pancreas and are usually detected at a later stage. Although curative resection is not possible in most of these tumors, both symptom and tumor control can be achieved by a multidimensional approach, to enable a long survival of most patients. Read More

View Article and Full-Text PDF
October 2019

[A Case of WDHA Water Diarrhea Hypokalemia Achlorhydria Syndrome that Developed after Multimodal Therapy for Retroperitoneal Paraganglioma].

Hinyokika Kiyo 2019 Jul;65(7):277-282

The Department of Urology, Hokkaido University Hospital.

A 45-year-old woman visited a local clinic with left-flank abdominal pain. Abdominal computed tomography (CT) revealed a tumor 20 cm in diameter in the left adrenal gland. She was referred to our hospital for further treatment. Read More

View Article and Full-Text PDF

Pancreatic neuroendocrine microadenomatosis presenting as a functional VIPoma.

J Surg Case Rep 2019 Jun 28;2019(6):rjz196. Epub 2019 Jun 28.

St. Vincent Hospital General Surgery Residency Program, St. Vincent Hospital Indianapolis, St. Vincent Ortho Center 2001 West 86th Street, Indianapolis, IN, USA.

Pancreatic microadenomas are benign tumors of neuroendocrine origin less than 5 mm in size. Whereas most microadenomas are non-functional; a few rare functional pancreatic microadenomas have been described in the setting of multiple endocrine neoplasia type one (MEN-1). In this report, we describe a unique case of multiple functional microadenomas of the pancreatic head in a patient who presented with persistent secretory diarrhea, refractory hypokalemia, metabolic acidosis and elevated plasma vasoactive intestinal peptide (VIP) levels. Read More

View Article and Full-Text PDF

Diagnostic and Management Challenges in Vasoactive Intestinal Peptide Secreting Tumors: A Series of 15 Patients.

Pancreas 2019 08;48(7):934-942

Centre for Gastroenterology, Neuroendocrine Tumor Unit, ENETS Centre of Excellence, Royal Free Hospital, London, United Kingdom.

Objectives: Vasoactive intestinal peptide-secreting tumors (VIPomas) are rare functioning neuroendocrine tumors often characterized by a difficult-to-control secretory syndrome and high potential to develop metastases. We hereby present the characteristics of 15 cases of VIPomas and provide a recent literature review.

Methods: This was a retrospective data analysis of 15 patients with VIPoma from 3 different centers and literature research through PubMed database during the last 10 years. Read More

View Article and Full-Text PDF

Life-threating diarrhea and acute renal failure secondary to pancreatic VIPoma treated by surgery.

Rev Esp Enferm Dig 2019 Aug;111(8):641-643

Hospital Clínico Universitario de Valencia.

Pancreatic neuroendocrine tumors represent less than 5% of all pancreatic tumors. They are a heterogeneous group of neoplasms with a diverse behavior and prognosis. Pancreatic vasoactive intestinal polypeptide tumor (VIPoma) is an exceptional tumor within this group due to its low incidence. Read More

View Article and Full-Text PDF

Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.

J BUON 2019 Mar-Apr;24(2):415-423

1st Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.

Purpose: Vasoactive intestinal peptide (VIP) secreting tumor (VIPoma) constitutes a rare functional neuroendocrine tumor that most often originates from pancreatic islet cells and presents as a sporadic, solitary neoplasm of the pancreas. The purpose of this study was to systematically review the literature of pancreatic VIPomas and report clinicopathologic data and treatment modalities for this rare entity.

Methods: A systematic literature search was performed. Read More

View Article and Full-Text PDF
December 2019

Chronic Diarrhea Secondary to Newly Diagnosed VIPoma.

Case Rep Gastroenterol 2019 Jan-Apr;13(1):225-229. Epub 2019 Apr 23.

Division of Gastroenterology and Hepatology, Northwestern University, Chicago, Illinois, USA.

Vasoactive intestinal polypeptide-secreting tumors (VIPoma) are a rare pancreatic neuroendocrine tumor that can cause chronic diarrhea with 1 case per 10 million people per year. Diagnosis is made based on a combination of laboratory evaluation (serum VIP level), imaging findings (functional positron emission tomography-computed tomography [PET-CT]), and histological analysis (chromogranin A stain). We present a case of a male with 6 months of diarrhea and malaise who was found to have significant kidney injury and hypokalemia requiring admission to the medical intensive care unit. Read More

View Article and Full-Text PDF